| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $11,099,620 | 4 | 25 |
Sells | $1,939,461 | 12 | 75 |
| EcoR1 Capital, LLC | 10 percent owner | 4 | $11.1M | 0 | $0 | $11.1M |
| FENTON DENNIS M | director | 0 | $0 | 1 | $45,182 | $-45,182 |
| Lizzul Paul F. | Chief Medical Officer | 0 | $0 | 4 | $276,930 | $-276,930 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 0 | $0 | 2 | $492,461 | $-492,461 |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $523,305 | $-523,305 |
| RENTON HOLLINGS | director | 0 | $0 | 3 | $601,584 | $-601,584 |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Over the last 12 months, insiders at AnaptysBio, Inc. have bought $11.1M and sold $1.94M worth of AnaptysBio, Inc. stock.
On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $32.52M and sold $4.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $11.1M.
The last purchase of 6,646 shares for transaction amount of $86,070 was made by EcoR1 Capital, LLC () on 2025‑01‑02.
| 2025-01-02 | EcoR1 Capital, LLC | 6,646 0.0216% | $12.95 | $86,070 | +31.51% | |||
| 2024-12-31 | EcoR1 Capital, LLC | 13,268 0.0426% | $12.93 | $171,513 | +32.59% | |||
| 2024-12-30 | EcoR1 Capital, LLC | 65,184 0.2122% | $12.92 | $842,060 | +32.68% | |||
| 2024-11-29 | Sale | RENTON HOLLINGS | director | 10,000 0.0329% | $25.00 | $250,000 | -30.21% | |
| 2024-09-23 | Sale | Lizzul Paul F. | Chief Medical Officer | 1,500 0.0054% | $38.67 | $58,005 | -46.42% | |
| 2024-09-17 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 3,780 0.0128% | $38.41 | $145,191 | -48.56% | |
| 2024-09-16 | Sale | Lizzul Paul F. | Chief Medical Officer | 2,220 0.0074% | $38.93 | $86,425 | -49.82% | |
| 2024-09-16 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 8,720 0.0297% | $39.82 | $347,270 | -49.82% | |
| 2024-09-16 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 12,220 0.0417% | $39.91 | $487,725 | -49.82% | |
| 2024-08-14 | Sale | Lizzul Paul F. | Chief Medical Officer | 2,000 0.0088% | $40.00 | $80,000 | -42.32% | |
| 2024-08-14 | EcoR1 Capital, LLC | 10 percent owner | 273,972 1.095% | $36.50 | $10M | -42.32% | ||
| 2024-07-18 | Sale | Lizzul Paul F. | Chief Medical Officer | 1,500 0.0056% | $35.00 | $52,500 | -40.15% | |
| 2024-07-15 | Sale | RENTON HOLLINGS | director | 10,000 0.0463% | $30.64 | $306,422 | -36.53% | |
| 2024-06-21 | Sale | FENTON DENNIS M | director | 1,950 0.007% | $23.17 | $45,182 | -11.21% | |
| 2024-06-18 | Sale | RENTON HOLLINGS | director | 1,950 0.007% | $23.16 | $45,162 | -6.55% | |
| 2024-05-22 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 1,500 0.0052% | $23.72 | $35,580 | -12.14% | |
| 2024-03-25 | Sale | Faga Daniel | CEO | 3,000 0.0114% | $21.42 | $64,268 | +12.11% | |
| 2024-03-22 | Sale | Faga Daniel | CEO | 145,940 0.5734% | $22.78 | $3.33M | +9.18% | |
| 2024-02-16 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 5,000 0.0195% | $25.00 | $125,000 | +0.62% | |
| 2024-01-30 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 3,065 0.0114% | $23.63 | $72,425 | +1.34% |
| EcoR1 Capital, LLC | 7880094 26.8208% | $163.95M | 13 | 0 | +15.76% | |
| Lizzul Paul F. | Chief Medical Officer | 15398 0.0524% | $320,355.39 | 0 | 6 | |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 4744 0.0161% | $98,698.92 | 0 | 6 | |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 3240 0.011% | $67,408.20 | 0 | 12 | |
| FENTON DENNIS M | director | 1950 0.0066% | $40,569.75 | 0 | 1 | |
| RENTON HOLLINGS | director | 1950 0.0066% | $40,569.75 | 0 | 3 | |
| NODELMAN OLEG | 7521024 25.5987% | $156.47M | 1 | 1 | +12.85% | |
| Novo Holdings A/S | 10 percent owner | 1936604 6.5915% | $40.29M | 1 | 8 | +59% |
| Topper James N | 1045031 3.5569% | $21.74M | 1 | 0 | +59% | |
| Faga Daniel | CEO | 749087 2.5496% | $15.58M | 0 | 3 | |
| Frazier Healthcare V, LP | 10 percent owner | 311291 1.0595% | $6.48M | 1 | 0 | +59% |
| Frazier Healthcare VII, L.P. | 10 percent owner | 311291 1.0595% | $6.48M | 1 | 0 | +59% |
| Lydon Nicholas | director | 271106 0.9227% | $5.64M | 1 | 1 | +59% |
| Suria Hamza | President, CEO | 68600 0.2335% | $1.43M | 0 | 10 | |
| Londei Marco | Chief Medical Officer | 22377 0.0762% | $465,553.49 | 0 | 3 | |
| Ware J. Anthony | director | 3600 0.0123% | $74,898.00 | 1 | 0 | +16.44% |
| Avalon Ventures VII L P | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Piscitelli Dominic | Chief Financial Officer | 0 0% | $0 | 0 | 1 |
$47,282,828 | 47 | -17.38% | $548.33M | |
$97,176 | 41 | 42.84% | $664.19M | |
$678,065,999 | 37 | -13.32% | $628.78M | |
$94,912,877 | 34 | -7.15% | $590.12M | |
$149,456,352 | 27 | -8.77% | $593.99M | |
$169,638,586 | 22 | 30.82% | $586.05M | |
$22,007,592 | 17 | -0.43% | $688.7M | |
AnaptysBio, Inc. (ANAB) | $124,557,176 | 16 | 29.13% | $611.26M |
$104,137,421 | 15 | 21.28% | $709.99M | |
$3,287,638 | 15 | -0.23% | $542.79M | |
$18,945,106 | 14 | -27.94% | $620.37M | |
$4,210,269 | 14 | -15.87% | $689.14M | |
$103,194,328 | 13 | 9.02% | $637.57M | |
$278,247,340 | 12 | 58.08% | $623.45M | |
$92,357,691 | 12 | 87.24% | $570.24M | |
$20,499,451 | 9 | 71.54% | $567M | |
$91,721,700 | 9 | -13.73% | $557.08M | |
$49,165,200 | 7 | 12.92% | $651.55M | |
$13,900 | 1 | -39.25% | $607.14M |
| Increased Positions | 89 | +52.05% | 13M | +35.21% |
| Decreased Positions | 74 | -43.27% | 8M | -22.86% |
| New Positions | 45 | New | 4M | New |
| Sold Out Positions | 32 | Sold Out | 4M | Sold Out |
| Total Postitions | 186 | +8.77% | 41M | +12.35% |
| Ecor1 Capital, Llc | $166,838.00 | 25.4% | 7.87M | +78,452 | +1.01% | 2024-12-31 |
| Fmr Llc | $64,211.00 | 9.78% | 3.03M | -278,939 | -8.43% | 2024-12-31 |
| Blackrock, Inc. | $46,122.00 | 7.02% | 2.18M | -371,870 | -14.59% | 2025-03-31 |
| Vanguard Group Inc | $39,069.00 | 5.95% | 1.84M | +143,584 | +8.45% | 2024-12-31 |
| Fairmount Funds Management Llc | $38,491.00 | 5.86% | 1.82M | +2M | New | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $33,347.00 | 5.08% | 1.57M | -635,470 | -28.77% | 2024-12-31 |
| Tang Capital Management Llc | $28,201.00 | 4.29% | 1.33M | 0 | 0% | 2024-12-31 |
| Boxer Capital, Llc | $27,547.00 | 4.19% | 1.3M | 0 | 0% | 2024-09-30 |
| Boxer Capital Management, Llc | $27,547.00 | 4.19% | 1.3M | +1M | New | 2024-12-31 |
| State Street Corp | $27,245.00 | 4.15% | 1.29M | +379,573 | +41.89% | 2024-12-31 |